SCHEDULE: Invus Group Discloses Stake in Hemab Therapeutics

Several entities affiliated with Invus Group and Raymond Debbane have reported beneficial ownership of Hemab Therapeutics Holdings, Inc. common stock, collectively holding 5.1% of the outstanding shares.

Summary

• This filing is a Schedule 13G, indicating a passive investment stake by several entities and an individual associated with Invus Group and Raymond Debbane in Hemab Therapeutics Holdings, Inc.
• The reporting persons collectively beneficially own 2,366,235 shares of Hemab Therapeutics Holdings, Inc. common stock.
• This represents 5.1% of the class of securities outstanding as of May 8, 2026.
• The filing details the beneficial ownership of Invus Public Equities, L.P., Invus Public Equities Advisors, LLC, Invus Global Management, LLC, Siren, L.L.C., Avicenna Life Sci Master Fund LP, Avicenna Life Sci Master GP LLC, Ulys, L.L.C., and Mr. Raymond Debbane.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily an update on beneficial ownership rather than a performance or strategic announcement.

Positives

• The filing indicates a significant passive investment by established entities, which could be interpreted as a vote of confidence in the company's long-term prospects.
• The reporting persons have sole voting and dispositive power over their respective holdings, indicating clear control over their investment decisions.

Negatives

• The filing does not contain any financial performance data or operational updates, limiting its insight into the company's current health.
• The passive nature of the investment means it does not necessarily imply active support or strategic involvement from the reporting persons.

Risks

• The primary risk is that the passive stake could be liquidated, potentially impacting the stock price if a large number of shares are sold.
• Changes in beneficial ownership, even if passive, can sometimes precede more active strategic moves or shifts in market sentiment.

Future Outlook

This filing is a Schedule 13G and does not contain forward-looking statements or guidance regarding the company's future performance.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in publicly traded companies. This filing indicates a passive investment by entities associated with Invus Group and Raymond Debbane in the biotechnology sector, specifically in Hemab Therapeutics Holdings, Inc.

Comparison to Industry Standards

• This filing is a standard Schedule 13G disclosure for beneficial ownership, not a performance report, making direct comparison to industry financial standards difficult.
• The 5.1% stake is a notable but not controlling interest, typical for institutional investors who may hold similar or larger stakes in other biotechnology companies.

Stakeholder Impact

• Shareholders: The disclosure of a significant passive stake may influence investor perception, but the immediate impact is likely minimal unless shares are traded.
• Management: The company's management will be aware of the significant beneficial ownership reported by these entities.

Next Steps

• The reporting persons will continue to monitor their investment in Hemab Therapeutics Holdings, Inc.
• Future filings will be made if there are material changes in beneficial ownership or other reportable events.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, Hemab Therapeutics, Invus Group, Raymond Debbane, Investment Stake, Common Stock